EGFR antibody (AA 956-985)

Catalog No. ABIN391933

This Rabbit Polyclonal antibody specifically detects EGFR in WB. It exhibits reactivity toward Human.

Quick Overview for EGFR antibody (AA 956-985) (ABIN391933)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EGFR antibody is un-conjugated

Application: Western Blotting (WB)

Clone: RB10971

Product Details anti-EGFR Antibody

Binding Specificity: AA 956-985

Predicted Reactivity: M

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This EGFR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 956-985 amino acids from human EGFR.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

Target Details for EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Alternative Name: EGFR

Background: EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Molecular Weight: 134277

Gene ID: 1956

NCBI Accession: NP_005219, NP_958439, NP_958440, NP_958441

UniProt: P00533

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins